Investigational drug · Phase 2
INE963
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uncomplicated Plasmodium Falciparum Malaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
4
Any phase or sponsor naming "INE963"
First trial start
2024
Jan 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INE963", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uncomplicated Plasmodium Falciparum Malaria
Approved drugs for the same conditions: Malaria · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "INE963" as an intervention, largest first.
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05750628 · 327 participants (planned) · Start Jan 23, 2024 · Primary completion Jun 9, 2026
Drug: INE963; KAE609 (Cipargamin) and 2 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 12 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07811882 · 95 participants · Start Oct 10, 2025 · Primary completion Jun 17, 2026
Drug: KAE609 (Cipargamin); SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04896632 · 64 participants · Start May 13, 2021 · Primary completion Nov 24, 2022
Drug: INE 963 · For: Healthy Volunteers
Sites: Mere Way, United Kingdom
Novartis PharmaceuticalsNovartis (NVS)
NCT07235020 · 52 participants · Start Jan 23, 2024 · Primary completion Jan 30, 2025
Drug: INE963 · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Azaguié, Côte d’Ivoire; Lambaréné, Gabon · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- INE963: A repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii.
She P, Liu Y, Li M, et al. · Microbiol Res 2026
- Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.
Sarma K, Sarma H, Deka J · Infection 2026
- The non-artemisinin antimalarial drugs under development: a review.
Okwu DG, Zoleko Manego R, Duparc S, et al. · Clin Microbiol Infect 2025
- Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs.
Soulama A, Sogore F, Ansah F, et al. · Microbiol Spectr 2025
- Recent developments in antimalarial drug discovery.
Umumararungu T, Nkuranga JB, Habarurema G, et al. · Bioorg Med Chem 2023
- Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria.
Taft BR, Yokokawa F, Kirrane T, et al. · J Med Chem 2022
Also in development for Uncomplicated Plasmodium Falciparum Malaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.